Recent Advances in the Management of Gastro-Oesophageal Reflux Disease (Q36924121)

17 August 2017

1 reference

title

Recent advances in the management of gastro-oesophageal reflux disease (English)

1 reference

17 August 2017

Recent Advances in the Management of Gastro-Oesophageal Reflux Disease (English)

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

20 November 2022

author name string

Klinkenberg-Knol EC

1

1 reference

17 August 2017

E. C. Klinkenberg-Knol

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:1775934

20 November 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1775934

20 November 2022

publication date

1 January 1991

1 reference

full work available at URL

17 August 2017

http://www.tandfonline.com/doi/pdf/10.3109/00365529109111237

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Scandinavian Journal of Gastroenterology. Supplement

20 November 2022

published in

1 reference

17 August 2017

volume

188

1 reference

17 August 2017

page(s)

101-107

1 reference

Sleeping on a wedge diminishes exposure of the esophagus to refluxed acid

17 August 2017

cites work

4

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Effects of sleeping with the bed-head raised and of ranitidine in patients with severe peptic oesophagitis

20 November 2022

5

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Ethanol-induced acute esophageal motor dysfunction

20 November 2022

9

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Smoking and pH response to H2-receptor antagonists

20 November 2022

10

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Aetiological factors in hepatocellular cancer

20 November 2022

12

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Cimetidine, metoclopramide, or placebo in the treatment of symptomatic gastroesophageal reflux

20 November 2022

14

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Cisapride versus placebo in reflux esophagitis. A multicenter double-blind trial

20 November 2022

19

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Combined therapy with cisapride and cimetidine in severe reflux oesophagitis: a double blind controlled trial

20 November 2022

22

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Symptomatic effect of a low-dose antacid regimen in reflux oesophagitis

20 November 2022

25

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Ranitidine and high-dose antacid in reflux oesophagitis. A randomized, placebo-controlled trial

20 November 2022

26

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Medical treatment of symptomatic hiatus hernia with low-density compounds

20 November 2022

27

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Clinical efficacy of sucralfate in reflux esophagitis. Comparison with cimetidine

20 November 2022

28

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Sucralfate in the treatment of reflux esophagitis in adults: an update

20 November 2022

29

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Sucralfate versus placebo in reflux esophagitis. A double-blind multicenter study

20 November 2022

30

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Sucralfate and alginate/antacid in reflux esophagitis

20 November 2022

31

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Sucralfate versus cimetidine in reflux esophagitis. A single-blind multicenter study.

20 November 2022

32

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Combination therapy of sucralfate and cimetidine, compared with sucralfate monotherapy, in patients with peptic reflux esophagitis

20 November 2022

36

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Bismuth subsalicylate reduces peptic injury of the oesophagus in rabbits

20 November 2022

37

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi

20 November 2022

38

93

67

Balan G

1989

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Treatment of ulcerative reflux oesophagitis with colloidal bismuth subcitrate in combination with cimetidine

20 November 2022

39

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Treatment of reflux oesophagitis with trimoprostil

20 November 2022

40

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Prostaglandins and the gastrointestinal mucosa: are they important in its function, disease, or treatment?

20 November 2022

41

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Histamine-2-receptor antagonists in gastro-oesophageal reflux

20 November 2022

44

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Treatment of reflux oesophagitis with ranitidine

20 November 2022

46

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Cimetidine in treatment of reflux oesophagitis with peptic stricture

20 November 2022

47

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Healing and relapse of reflux esophagitis during treatment with ranitidine.

20 November 2022

50

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Gastric acid hypersecretion in refractory gastroesophageal reflux disease.

20 November 2022

52

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

The effects of omeprazole and ranitidine on 24-hour pH in the distal oesophagus of patients with reflux oesophagitis

20 November 2022

54

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Cimetidine and metoclopramide in oesophageal reflux disease.

20 November 2022

55

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Treatment of severe reflux esophagitis with cimetidine and metoclopramide

20 November 2022

56

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Inhibition of basal and betazole- and sham-feeding-induced acid secretion by omeprazole in man

20 November 2022

57

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Healing and relapse of severe peptic esophagitis after treatment with omeprazole

20 November 2022

58

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis

20 November 2022

59

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis

20 November 2022

61

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Omeprazole or ranitidine in the treatment of reflux esophagitis. Results of a double-blind, randomized, Scandinavian multicenter study

20 November 2022

62

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Omeprazole or high-dose ranitidine in the treatment of patients with reflux oesophagitis not responding to 'standard doses' of H2-receptor antagonists.

20 November 2022

63

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Use of omeprazole in the management of reflux oesophagitis resistant to H2-receptor antagonists

20 November 2022

66

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion

20 November 2022

67

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Medical therapy for chronic reflux esophagitis. Long-term follow-up

20 November 2022

68

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Healing, relapse rates and prophylaxis of reflux esophagitis.

20 November 2022

69

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Combined gastric and oesophageal 24-hour pH monitoring and oesophageal manometry in patients with reflux disease, resistant to treatment with omeprazole.

20 November 2022

70

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Schweizerische medizinische Wochenschrift

20 November 2022

71

112

1901

Koelz H R

1982

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Long-term therapy for chronic gastroesophageal reflux

20 November 2022

74

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Gastroenterology International

20 November 2022

75

author name string

Dent J

publication date

1988

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Prevention of Relapse of Reflux Esophagitis after Endoscopic Healing: The Efficacy and Safety of Omeprazole Compared with Ranitidine

20 November 2022

77

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Omeprazole in the treatment of erosive oesophagitis refractory to high dose cimetidine and ranitidine

20 November 2022

78

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Maintenance treatment with ranitidine compared with fundoplication in gastro-oesophageal reflux disease

20 November 2022

80

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

Surgical treatment of gastroesophageal reflux in ten patients with severe asthma

20 November 2022

83

1 reference

https://api.crossref.org/works/10.3109/00365529109111237

20 November 2022

Identifiers

0 references

1 reference